ROC Inc.

ROC Inc Trivia Night

ROC Inc Trivia Night Book now to help us raise money for vital ovarian cancer research. Saturday 1 June 2019, 7PM Warilla Bowls and Recreation Club Event Details Rare Ovarian cancer Incorporate also fondly known as ROC Inc is a Not For Profit charity that started in the Illawarra February 2018, raising awareness for Ovarian cancer and it’s symptoms and raising money for vital research for Juvenile Granulosa Cell Tumour (JGCT) a rare and incurable ovarian cancer that a local in the Illawarra child was diagnosed with at 16years old. The research which is now the world’s largest for JGCT […]

One-two punch could knock out rare ovarian cancer

A double-barrelled, non-surgical treatment could deliver the knock-out punch for a rare type of ovarian cancer.
Granulosa cell tumours of the ovary have a high rate of recurrence and available treatments are nearly always unsuccessful. Now a combination treatment that tackles the body’s defence mechanisms may prove a game-changer.

Retreatment with aromatase inhibitor therapy in the management of granulosa cell tumor

Highlights Over 90% of granulosa cell tumors have a FOXL2 mutation that contributes to aromatase upregulation. Chemotherapy has demonstrated limited efficacy in the treatment of granulosa cell tumors. A patient with recurrent granulosa cell tumor responded briefly to anastrazole treatment. Retreatment with another aromatase inhibitor letrozole led to a durable response of 24 months. Read Full Article Introduction Granulosa cell tumors (GCTs) represent 3% to 5% of ovarian neoplasms. These tumors arise from the sex-cord stromal cells of the ovary (Colombo et al., 2007). Characteristically, GCTs produce inhibin (Lappöhn et al., 1989) and express aromatase activity promoting estrogen synthesis (Kato et al., 2015). There are two subtypes of GCTs, adult and juvenile, with the former comprising 95% of cases.Most cases of GCT are […]

Zejula Maintenance Therapy Extends Survival With Toxicities in Recurrent Ovarian Cancer

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial. “This TWiST (time without symptoms or toxicity) analysis benefit means that patients treated with niraparib experienced more progression-free time without symptoms or toxicities due to nausea, vomiting, or fatigue compared to placebo,” Ursula A. Matulonis, M.D., director and chief of gynecologic oncology at Dana-Farber Cancer Institute, said during her presentation at the 50th SGO Annual Meeting, held March 16-19 in Honolulu, Hawaii. In the multicenter, double-blind, randomized-controlled trial, patients with […]

Wings of Awareness on the Move – Warilla Grove

Our Wings of Awareness will be at Warilla Grove Shopping Center. Monday 11 to Wednesday 13 March. Come along and help create awareness by having your picture taken with our bold and beautiful Awareness Wings and posting to your social media accounts with the hashtag #RockforROC. Located at 43 – 57 Shellharbour Road, Warilla. Learn More

Rock for ROC Family Fun Day

Help us promote this event – Download Our Poster Saturday 9 February 2019 Lakeview Hotel Rare Ovarian cancer Incorporated (ROC Inc.) together with the Lakeview Hotel are delighted to announce a fundraising event on the 9th February to raise money for research for a Rare Ovarian cancer called Juvenile Granulosa Cell Tumour (JGCT). A local child in Oak Flats was diagnosed with just after her 16th Birthday. The youngest case in Australia was diagnosed at 11months old. This is an incurable disease but through research it can be a curable cancer. Come along and be apart of this fundraising event to […]